New Delhi: The real-world data of Russian Sputnik V vaccine obtained during mass vaccinations in Argentina, Bahrain, Hungary, Mexico, Russia, Serbia, the Philippines and UAE demonstrate lack of serious adverse events (such as CVTs or myocarditis).
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), investor in the Russian Sputnik V vaccine against coronavirus, announces the results of its joint work with Ministries of Health and regulators of the leading countries to collect and analyze real world vaccination data on the first anniversary of the vaccine’s registration confirming its high safety and efficacy profile.
On the first anniversary of Sputnik V registration official data from leading countries confirms the vaccine’s high safety and efficacy profile.
In several countries where multiple vaccines are used, the Russian vaccine has demonstrated one of the best safety and efficacy parameters.
Sputnik V has also pioneered the unique heterogeneous boosting (vaccine cocktail) approach based on use of two different human adenoviral vectors for two injections in the course of vaccination to achieve stronger and more durable immunity. This has become the core of the partnership of Sputnik V with other producers and this approach is now being followed by other producers as they try their own vaccine combinations.
Read: Govt gives nod to conduct study on mixing Covaxin, Covishield
To date Sputnik V has been approved in 69 countries with a total population exceeding 3.7 billion people - nearly half of the global population. RDIF has concluded production partnerships with more than 20 companies in 14 countries, including the leading manufacturers in India, China, South Korea, Argentina, Mexico and other countries.
Vaccination with Sputnik V has produced protective neutralizing titers against new variants, including Alpha B.1.1.7 (first identified in UK), Beta B.1.351 (first identified in South Africa), Gamma P.1 (first identified in Brazil), Delta B.1.617.2 and B.1.617.3 (first identified in India) and Moscow endemic variants B.1.1.141 and B.1.1.317 with mutations in the receptor-binding domain (RBD).
In addition to the two-dose Sputnik V vaccine, the single dose Sputnik Light vaccine is also demonstrating high safety and efficacy results in Argentina. Sputnik Light is the first component of Sputnik V (recombinant human adenovirus serotype number 26 (rAd26)).
In particular, data from the Ministry of Health of the province of Buenos Aires showed that Sputnik Light had helped to elicit antibodies in 94 percent of those vaccinated and provided for a strong immune response.
